WP
ORKA

Woodline Partners’s Oruka Therapeutics ORKA Stock Holding History

Woodline Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2M Buy
574,882
+329
+0.1% +$11.4K 0.11% 257
2025
Q4 		$17.4M Buy
574,553
+223
+0% +$6.21K 0.07% 341
2025
Q3 		$11M Buy
574,330
+183,426
+47% +$2.72M 0.05% 422
2025
Q2 		$4.38M Buy
390,904
+100
+0% +$1.04K 0.02% 588
2025
Q1 		$4.01M Sell
390,804
-165
-0% -$2.06K 0.03% 558
2024
Q4 		$7.58M Buy
390,969
+174
+0% +$4.25K 0.05% 408
2024
Q3 		$9.58M Buy
+390,795
New +$13.6M 0.08% 299

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Woodline Partners's ORKA Position: Q1 2026 in Review

Woodline Partners increased its Oruka Therapeutics (ORKA) stake by 0.06% in Q1 2026, buying an estimated $11.4K and bringing the position to 574,882 shares worth $28.2M. The position accounts for 0.11% of the portfolio, ranked #257.

Woodline Partners first reported a position in ORKA in Q3 2024 and has held it in 7 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Woodline Partners held 574,882 shares of Oruka Therapeutics worth $28.2M as of Q1 2026.
  • Woodline Partners bought 329 Oruka Therapeutics shares in Q1 2026, an estimated $11.4K.
  • Oruka Therapeutics made up 0.11% of Woodline Partners's portfolio in Q1 2026, its #257 holding.
  • Woodline Partners first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.